Authors’ response: Oxygen therapy in heart failure
Notice bibliographique
Résumé
This correspondence refers to ‘Oxygen supplementation in ambulatory patients with heart failure: a randomized proof-of-concept study’, by M. Tremblay-Gravel et al. https://doi.org/10.1093/ehjopen/oeaf074. Authors’ response to the commentary of Kourek and Dimopoulos, https://doi.org/10.1093/ehjopen/oeaf121. We thank Kourek and Dimopoulos for their thoughtful commentary1 on our proof-of-concept study2 evaluating ambulatory oxygen therapy in patients with chronic heart failure (HF). We agree that the methodological and physiological considerations they raise are important, and we welcome the opportunity to clarify several points. First, we acknowledge the concerns regarding potential deleterious haemodynamic effects of hyperoxia. Experimental data suggest that high inspired oxygen concentrations can impair cardiac performance. However, whether these acute physiological changes translate into adverse clinical outcomes in chronic HF remains uncertain, leaving significant equipoise. We also note that the cited pilot work by Dimopoulos et al.3 was conducted in pulmonary arterial hypertension rather than HF, a distinct population in which extrapolation is not straightforward. This adds to the uncertainty and highlights the need for HF-specific evidence. Second, patient heterogeneity is another consideration. While some of our participants had a left ventricular ejection fraction above 40%, our study was not powered for subgroup analyses and its small sample size precludes meaningful segmentation of the population. More importantly, the field of HF is moving beyond a rigid ejection fraction–based framework, as several key therapies, including angiotensin receptor–neprilysin inhibitors, mineralocorticoid receptor antagonists, and SGLT2 inhibitors, have demonstrated benefits across the ejection fraction spectrum.4 All of our study participants shared the same hallmark symptoms of HF, namely, exertional dyspnoea and reduced functional capacity corroborated by elevated N-terminal pro-B-type natriuretic peptide, which were the focus of this exploratory trial. We also agree with the importance of disentangling the cardiac and pulmonary contributions to breathlessness. Although one patient had chronic obstructive pulmonary disease in our study, comorbid pulmonary disease is common in HF, and future studies should carefully characterize pulmonary function with spirometry in all patients. This is particularly relevant given that oxygen therapy has established benefits in chronic obstructive pulmonary disease and related conditions.5 Finally, we concur that in advanced or refractory HF, priorities may shift towards symptom relief even at the expense of potential physiological trade-offs. Patients sometimes place a higher value on quality of life than on longevity, and this perspective should inform the design and goals of future trials.6 It is essential that future clinical trials clearly define whether the aim is to improve HF outcomes or to provide palliative benefit. That said, there is not yet definitive evidence that oxygen therapy confers symptomatic benefit in HF. Our study was small, unblinded, and exploratory, and its results should be considered only as hypothesis-generating. In summary, we emphasize that our findings should not be extrapolated to routine clinical practice at this stage. Rather, they should stimulate the conduct of the larger, rigorous, and well-stratified studies that are needed to explore the role of ambulatory oxygen therapy in HF.
Récupéré en direct depuis OpenAlex et désinversé. Les résumés ne sont pas conservés dans cette base de données : les index inversés représentent 8,6 Go des 9,3 Go de texte de la base, et le serveur dispose de 13 Go libres.
Comment cette classification a été obtenuedéplier
Prédiction machine sur la base complète
Imitation des enseignantsNi prévalence calibrée, ni vérité terrain. Validation humaine à venir. Le volet Gemma est une étiquette directe du modèle pour chaque travail de la base, lue sur la notice réduite au titre. Le volet Codex est un classifieur appris des 10 348 étiquettes directes de Codex et calibré sur les taux pondérés de l'échantillon; les champs sans appui suffisant ne portent aucun appel Codex. Le mode candidate est l'union des deux volets; le consensus est leur intersection. Ces sorties portent le statut machine_predicted_unvalidated et ne sont pas des étiquettes humaines.
Scores du classifieur distillé par catégorie (deux têtes)
| Catégorie | Codex | Gemma |
|---|---|---|
| Métarecherche | 0,003 | 0,027 |
| Méta-épidémiologie (sens strict) | 0,001 | 0,001 |
| Méta-épidémiologie (sens large) | 0,002 | 0,002 |
| Bibliométrie | 0,001 | 0,001 |
| Études des sciences et des technologies | 0,004 | 0,003 |
| Communication savante | 0,004 | 0,003 |
| Science ouverte | 0,002 | 0,001 |
| Intégrité de la recherche | 0,070 | 0,045 |
| Charge utile insuffisante (le modèle a refusé de juger) | 0,010 | 0,007 |
Scores machine (provisoires)
Les deux têtes enseignantes du modèle étudiant, lues sur ce travail. Un score ordonne la base pour la relecture; il n'affirme jamais une catégorie, et le statut de validation accompagne chaque rangée tel quel.
Scores de référence d'un modèle non mature (critères de maturité non atteints, 7 itérations). Un score ordonne; il n'affirme jamais une catégorie.
score_only:v0-immature-baseline · tel quel depuis la passe de notation : score_only signifie que le nombre peut ordonner les travaux, et qu'aucune étiquette de catégorie n'en découleClassification
machine, non validéePrédiction automatique; un appel candidat d’une seule source (Gemma direct ou Codex distillé), pas un consensus.
Le détail, modèle par modèle et score par score, se trouve en fin de page sous « Comment cette classification a été obtenue ».